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Neurobiology of Disease
Negative Allosteric Modulation of mGluR5 Partially Corrects
Pathophysiology in a Mouse Model of Rett Syndrome
X Jifang Tao,1,2HaoWu,3,4,5 Amanda A. Coronado,1,2 Elizabeth de Laittre,1,2 XEmily K. Osterweil,6 Yi Zhang,3,4,5
and XMark F. Bear1,2
1Picower Institute for Learning and Memory and 2Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge,
Massachusetts 02139, 3Howard Hughes Medical Institute, Boston, Massachusetts 02115, 4Program in Cellular and Molecular Medicine, Boston Children’s
Hospital, Boston, Massachusetts 02115, 5Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, and 6Centre for Integrative
Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom
Rett syndrome (RTT) is caused by mutations in the gene encoding methyl-CpG binding protein 2 (MECP2), an epigenetic regulator of
mRNA transcription. Here, we report a test of the hypothesis of shared pathophysiology of RTT and fragile X, another monogenic cause
of autism and intellectual disability. In fragile X, the loss of the mRNA translational repressor FMRP leads to exaggerated protein
synthesis downstream of metabotropic glutamate receptor 5 (mGluR5). We found that mGluR5- and protein-synthesis-dependent syn-
aptic plasticity were similarly altered in area CA1 of Mecp2 KO mice. CA1 pyramidal cell-type-specific, genome-wide profiling of
ribosome-bound mRNAs was performed in wild-type andMecp2 KO hippocampal CA1 neurons to reveal the MeCP2-regulated “trans-
latome.” We found significant overlap between ribosome-bound transcripts overexpressed in theMecp2 KO and FMRP mRNA targets.
These tended to encode long genes that were functionally related to either cytoskeleton organization or the development of neuronal
connectivity. In the Fmr1KOmouse, chronic treatment withmGluR5-negative allostericmodulators (NAMs) has been shown to amelio-
rate many mutant phenotypes by correcting excessive protein synthesis. In Mecp2 KO mice, we found that mGluR5 NAM treatment
significantly reduced the level of overexpressed ribosome-associated transcripts, particularly those that were also FMRP targets. Some
Rett phenotypes were also ameliorated by treatment, most notably hippocampal cell size and lifespan. Together, these results suggest a
potential mechanistic link betweenMeCP2-mediated transcription regulation andmGluR5/FMRP-mediated protein translation regula-
tion through coregulation of a subset of genes relevant to synaptic functions.
Key words: autism; fragile X; intellectual disability; metabotropic glutamate receptor; Rett syndrome; synaptic protein synthesis
Introduction
Accumulating evidence suggests that aberrant synaptic protein
synthesis may contribute to the pathophysiology underlying au-
tism spectrum disorder (ASD) and intellectual disability (ID)
(Kelleher and Bear, 2008). Synaptic control of local protein syn-
thesis can be assayed in animal models by the study of synaptic
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Significance Statement
Altered regulation of synaptic protein synthesis has been hypothesized to contribute to the pathophysiology that underlies
multiple forms of intellectual disability and autism spectrumdisorder. Here, we show in amousemodel of Rett syndrome (Mecp2
KO) that metabotropic glutamate receptor 5 (mGluR5)- and protein-synthesis-dependent synaptic plasticity are abnormal in the
hippocampus. We found that a subset of ribosome-bound mRNAs was aberrantly upregulated in hippocampal CA1 neurons of
Mecp2KOmice, that these significantly overlappedwith FMRPdirect targets and/or SFARI human autismgenes, and that chronic
treatmentofMecp2KOmicewithanmGluR5-negative allostericmodulator tunesdownupregulated ribosome-boundmRNAsand
partially improves mutant mice phenotypes.
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long-term depression (LTD) induced by activation of metabo-
tropic glutamate receptor 5 (mGluR5) (Huber et al., 2000, Huber
et al., 2001). Studies over the past 15 years have shown that
protein-synthesis-dependent mGluR-LTD is altered in multiple
mouse models of ASD and ID, including those for fragile X, tu-
berous sclerosis, CYFIP1 and SYNGAP1 haplo-insufficiency, and
chromosome 16p11.2 microdeletion (Huber et al., 2002, Auer-
bach et al., 2011, Bozdagi et al., 2012, Barnes et al., 2015, Tian et
al., 2015). These results support the notion that aberrant regula-
tion of synaptic protein synthesis represents a point of conver-
gence for many varied gene mutations that manifest behaviorally
as ASD and ID.
Rett syndrome (RTT), affecting 1 in 10,000 females, is a severe
developmental disorder caused by mutations in an X-chromosome
gene encoding methyl-CpG binding protein 2 (MECP2). RTT pa-
tientshave seeminglynormaldevelopment for the first 6–18months
before entering the stage of regression. Major symptoms include
ASD, deceleration of head growth, loss of speech and purposeful
hand movements, gait abnormalities, and irregular breathing pat-
terns. The disease is rare in males because hemizygous mutation of
MECP2 leads to early lethality. Postmortemstudies showthatRTT is
not aneurodegenerativedisorder, butneurons inpatients’ brains are
smaller in size and more densely packed (for review, see Chahrour
andZoghbi, 2007).Heterozygous femalemicewithMecp2mutation
exhibit relatively subtle symptoms until 20 weeks or older, with var-
ied symptom onset age (Samaco et al., 2013). In contrast, hemizy-
gousMecp2KOmale (Mecp2 /y) mice recapitulate many clinically
relevant symptomatic features at an earlier age, including locomotor
deficits, irregular breathing with apneas, reduced neuronal soma
size,prematuredeath, andsevere learningandmemory impairment.
Therefore, male Mecp2 KO mice are often used as a functionally
relevant diseasemodel for revealing theunderlyingpathophysiology
of RTT (Chen et al., 2001, Guy et al., 2001).
MeCP2 selectively recognizes and binds to methylated cyto-
sines in the genome and acts as a major effector protein for this
epigenetic DNA modification (Lewis et al., 1992, Skene et al.,
2010, Guo et al., 2014, Gabel et al., 2015). Although overall gene
expression appears to be only modestly dysregulated in the ab-
sence ofMeCP2 (Tudor et al., 2002, Jordan et al., 2007, Chahrour
et al., 2008, Ben-Shachar et al., 2009, Gabel et al., 2015), MeCP2
was found recently to preferentially repress the transcription of
many long genes associated with relatively high levels of intra-
genic non-CpG methylation (Sugino et al., 2014, Chen et al.,
2015, Gabel et al., 2015). Moreover, MeCP2 may also regulate
microRNA expression and thereby exert an additional layer of
transcription/translation regulation (Szulwach et al., 2010,Wu et
al., 2010).
Because transcription and translation are in general tightly
coupled to allocate cellular resources efficiently (Li et al., 2014),
we set out to test the hypothesis that loss ofMeCP2 as a transcrip-
tion repressor may lead to downstream translational dysregula-
tion of a cohort of mRNAs that are under tight translational
control by an mGluR5/FMRP pathway. In the current study, us-
ing integrated approaches of electrophysiology, biochemistry,
genomics, and behavioral analyses, we find that in early symp-
tomatic Mecp2 KO mice, hippocampal mGluR-LTD is protein
synthesis independent and protein translation is abnormal, with
an increase in ribosome-associated mRNAs for long genes. Fur-
thermore, we provide evidence that manyMeCP2-repressed and
FMRP-bound mRNAs that are aberrantly upregulated inMecp2
KO may be tuned down by treatment with a negative allosteric
modulator of mGluR5, which suggests a mechanistic link be-
tween MeCP2-mediated transcription repression and FMRP-
mediated translation regulation. Finally, we demonstrate that
pharmacological modulation of the mGluR5 signaling pathway
partially ameliorates a subset of RTT phenotypes.
Materials andMethods
Animals.Mecp2 KO mice (Mecp2 tm1.1bird, 003890; The Jackson Labora-
tory) andWT littermates were maintained on a C57BL/6 background by
breedingMecp2 / females withWTmales from Charles River Labora-
tories (strain code: 027). The Cck-bacTRAP (GM39) line was provided
by Dr. Nathaniel Heintz of The Rockefeller University. In this mouse,
EGFP fused to the ribosomal protein L10a was inserted in the bacterial
artificial chromosome (BAC) in such away that expressionwas driven by
the cholecystokinin (Cck) promoter. All animal experimentation was
done in accordancewithNational Institutes ofHealth andMassachusetts
Institute of Technology guidelines. All experiments were performed on
littermate WT and Mecp2 KO mice with the experimenter blinded to
genotype.
Hippocampal slice physiology. Experiments were done as described pre-
viously (Auerbach et al., 2011). Acute hippocampal slices (350m)were
prepared using a vibroslicer from postnatal day 30 (P30) to P35 mice in
ice-cold dissection buffer containing the following (in mM): NaCl 87,
sucrose 75, KCl 2.5, NaH2PO4 1.25, NaHCO3 25, CaCl2 0.5, MgSO4 7,
ascorbic acid 1.3, and D-glucose 10 (saturated with 95% O2/5% CO2).
Immediately after slicing, the CA3 region was removed. Slices were re-
covered in artificial CSF (ACSF) containing the following (in mM): NaCl
124, KCl 5, NaH2PO4 1.23, NaHCO3 26, CaCl2 2,MgCl2 1, and D-glucose
10 (saturated with 95% O2/5% CO2) at 32.5°C for at least 3 h before
recording. Field EPSPs (fEPSPs)were evoked by stimulation of the Schaf-
fer collaterals and recorded from CA1 stratum radiatum. Chemical LTD
was induced by applying S-3,5-dihydroxyphenylglycine (DHPG, 50 M;
Sigma-Aldrich) for 5 min (Huber et al., 2001). For experiments with
cycloheximide treatment, slices were incubated in ACSF containing 60
M cycloheximide (Sigma-Aldrich) throughout the recording. The ini-
tial slope of the fEPSP was used to assess synaptic strength. Data were
normalized to the baseline response and are presented as mean SEM.
LTD was calculated by comparing the average response 55–60 min after
DHPG application with the average of the last 5 min of baseline. Wave-
forms shown are from all traces averaged from all animals at the time
points indicated. Genotype and drug effect were analyzed using two-way
ANOVA.
Immunoblotting. Hippocampal slices were lysed in Laemmli buffer
and equal amounts of protein were loaded and resolved in SDS-PAGE
and transferred onto nitrocellulose membrane. Total protein levels
were quantified by MemCode reversible protein stain (Pierce). The
following antibodies were used: phospho-ERK (p-ERK1/2; Thr202/
Tyr204), ERK1/2, phospho-Akt (p-AKT; Ser473), phosphorylated
mammalian target of rapamycin (p-mTOR; Ser2448), mTOR, p-S6
(Ser235/236), S6 (all from Cell Signaling Technology), mGluR5 (Ab-
cam), mGluR1 (BD Biosciences), and -actin (Abcam). Bands were
detected by chemiluminescence (ECL; GE Healthcare) or IR fluores-
cence (LI-COR). Quantifications were done with Quantity-One
(Bio-Rad). The relative expression levels of each protein were deter-
mined by the intensity of target immunoblot bands normalized to the
total protein level of each lane (MemCode intensity). A paired two-
tailed t test was used to determine whether differences between
genotypes were statistically significant at p  0.05.
Metabolic labeling. Protein synthesis measurements were done as
described previously with paired WT and Mecp2 KO littermates (Os-
terweil et al., 2010). Briefly, 500 m hippocampal slices were pre-
pared with a Stoelting tissue slicer and recovered for 3 h in 32.5°C
ACSF, incubated for 30 min with 25 M actinomycin D (EMD Bio-
sciences), and then transferred to ACSF with 10 Ci/ml 35SMet/Cys
(PerkinElmer) for 30 min. Labeled slices were homogenized in pro-
tein lysis buffer (10 mMHEPES, pH 7.4, 2 mM EDTA, 2 mM EGTA, 1%
TX100, and protease inhibitor; Roche) and unincorporated amino
acids were removed by precipitating proteins in the homogenate with
trichloroacetic acid. Isotope incorporation was measured with a scin-
tillation counter (Beckman). Protein concentration was measured by
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DC Protein assay (Bio-Rad). Protein synthesis rate was calculated as
counts per minute per microgram of protein and the reading was
normalized to the ACSF 35SMet/Cys counts. A paired two-tailed t test
was used to determine whether differences between genotypes were
statistically significant at p  0.05.
TRAP-seq and differential gene expression analysis. TranslatingmRNAs
were immunoprecipitated from acutely dissected hippocampal tissue
and purified as described previously (Heiman et al., 2008, Heiman et al.,
2014). RNA samples were analyzed with a Bioanalyzer (Agilent) to con-
firm RNA integrity (RIN 7). RNA concentrations were determined
with the Quant-it Ribogreen RNA assay (Life Technologies). Purified
RNA (11.5 ng) was converted to cDNAs with Ovation RNA-seq V2
system (NuGEN). A total of 500 ng of cDNAs from each sample were
fragmented to 200 bp using a Covaris S2 ultrasonicator. Fragmented
cDNA (100 ng) was end-repaired, dA-tailed, and ligated to adaptors
using the NEBNext Ultra DNA library prep kit (New England Biolabs).
Sequencing libraries were prepared using the KAPAHiFi Hotstart Ready
Mix PCR Kit (Kapa Biosystems) and NEBNext Multiplex Oligos for Il-
lumina (Index Primers Set1 and 2). Library quality was examined with
the Qubit dsDNA HS Assay Kit (Life Technologies) and Bioanalyzer
using a High Sensitivity DNA kit (Agilent). Final concentrations of se-
quencing libraries were quantified by qPCR using KAPA Library Quan-
tification Kit (Kapa Biosystems). TRAP-seq libraries were sequenced on
a HiSeq 2500 or a NextSeq 500 Sequencer (Illumina). Sequencing reads
(50 bp, single-end) were first mapped to the Mus musculus primary as-
sembly reference genome (Gencode GRCm38/release M6) using STAR-
2.4.2a. Uniquely mapped reads that overlapped with exons of known
protein coding genes were counted using htseq-count python script.
Differential expression was calculated using DESeq2 (Love et al., 2014)
and p-values were adjusted for multiple testing using the Benjamini–
Hochberg procedure (GEO accession number: GSE82068).
Gene set enrichment analysis (GSEA). GSEA analysis was performed as
described previously (Subramanian et al., 2005) using a modified
GSEA.1.0 R script (implemented in R-3.1.3). Normalized enrichment
score and statistical significance were estimated by comparison with a
null model generated by permuting the gene labels randomly 1000 times.
FMRP direct targets used in GSEA analysis were downloaded from the
FMRP HITS-CLIP dataset (Darnell et al., 2011).
Gene ontology (GO) analysis. GO analysis (see Fig. 3d) was performed
using the DAVID version 6.7 bioinformatics resource http://david.abcc.
ncifcrf.gov/	.
Protein–protein network analyses. Protein–protein interaction (PPI)
network analysis was performed using the GeNets program https://
www.broadinstitute.org/genets	 and the InWeb PPI database. A set of
genes (nodes in the network) was grouped as a PPI community if they
were more connected to one another than they were to other groups of
genes. Curated and computationally derived PPIs were shown as lines.
Each PPI interaction was assigned a credibility score between 0 and 1,
where 1 s are “gold standard interactions,” indicated by thick black lines.
The scores other than 1 were defined based on the number of citations
and types of experiments that lend evidence toward the interaction. The
connectivity p-value indicates whether the observed PPI network is sig-
nificantly more connected than expected for a random gene set of same
size. GSEA was performed using a Bonferroni-adjusted hypergeometric
test and only the C2 set (4722 curated gene sets from BioCarta, KEGG,
Reactome, PID, etc.) from theMolecular Signatures Database (MSigDB)
was considered during this analysis. SFARI genes were downloaded
from the SFARI human gene collection https://gene.sfari.org/autdb/
Welcome.do	.
CTEP treatment. Chronic CTEP treatment (0.4 mg/kg) was adminis-
tered via subcutaneous injection (for mice younger than P30) or oral
gavage (for mice older than P30) once every 48 h. This dose was chosen
after a pilot study revealed that the dose of 2 mg/kg used in previous
studies in fragile X (Michalon et al., 2012) and 16p11.2 microdeletion
(Tian et al., 2015) mouse models caused significant weight loss in the
Mecp2mice.
Whole-body plethysmography. Breathing was recorded in awake and un-
restrainedmice using whole-body plethysmography (EMKATechnologies)
with a constant inflow of fresh air (0.8 L/min). Mice were habituated to the
chamber for 20min1dbeforebeing recording forup to1.5h.Rawdatawere
exported and analyzed inMatlab (TheMathWorks).
Immunohistochemistry and soma size analyses.Micewere perfusedwith
PBS, followed by 4% paraformaldehyde (PFA), and brains were sliced
into 50-m-thick sections in PBS with a vibratome (Leica). Brain sec-
tions were blocked and permeabilized for 1 h at room temperature in a
blocking buffer of 1
PBS with 5% normal donkey serum and 0.16%
Triton X-100. For immunostaining, sections were incubated with pri-
mary antibody overnight, washed 3 times with PBS, incubated with sec-
ondary antibody for 1.5 h, washed 3 times with PBS, and then mounted
onto slides and coverslipped. The following antibodies were used for
immunostaining: GFP (Abcam, rabbit polyclonal, 1/1500), NeuN (EMD
Millipore, mouse monoclonal, 1/500). For Nissl staining, permeabilized
brain sections were incubated with Neurotrace (Life Sciences, 1/100) for
30 min at room temperature, washed 3 times with PBS, and then
mounted onto slides and coverslipped. Images were taken with a confo-
calmicroscope.Only neuronswith clear nuclei were quantified and soma
sizes were analyzed with Fiji (ImageJ) software by an experimenter
blinded to genotype and treatment. Two sample Kolmogorov–Smirnov
(KS) tests were used to determine whether the differences between each
genotype/treatment (based on cell number) were statistically significant.
Two-way ANOVA was used to determine whether the differences be-
tween genotype/treatment were statistically significant (based on aver-
aged soma size per animal).
Open-field test. Locomotor activity was measured with an open-field
test as described previously (Crittenden et al., 2014). Mice were habitu-
ated to a test room with dim light for 15 min before being placed into 25
cm (W)
 25 cm (L)
 40 cm (H) arenas surrounded by Plexiglas walls
with an activitymonitoring system (TrueScan; Coulbourn Instruments).
The sensor ring with infrared beamsmeasured animal position every 100
ms and the software calculated the distance traveled in 5 min bins for a
total time of 20 min per day for 2 consecutive days. Two-way ANOVA
was used to determine whether the differences between genotype/treat-
ment were statistically significant.
Inhibitory avoidance test. Inhibitory avoidance test was performed as
described previously (Do¨len et al., 2007, Michalon et al., 2012). Mice
were placed in the lit compartment of a two-chamber box for 90 s before
the shutter separating the two compartments opened. At 0 h training
time, once the animal entered the dark compartment, it received a single
foot shock of 0.5 mA for 2 s. Mice then stayed in the dark compartment
for 120 s before being returned to their home cages. Mice were placed
back in the lit chamber at 24 and 48 h after conditioning to measure the
latency to enter the dark compartment. They were enclosed in the dark
compartment for 120 s without receiving any additional foot shock at 24
and 48 h time points. Two-way repeated-measures (RM) ANOVA was
used to determine whether the differences between genotype/treatment
were statistically significant.
Contextual fear conditioning. Mice were fear conditioned to the train-
ing context with a single foot shock of 0.8 mA for 2 s as described previ-
ously (Auerbach et al., 2011). They were returned 24 h later either to the
same context or to a novel context (varying distal cues, odor, lighting,
and floor material). Conditioned fear response was assessed by measur-
ing the percentage of time spent freezing during a test period of 3 min.
Two-way ANOVA was used to determine whether the differences be-
tween genotype/treatment were statistically significant.
Elevated plusmaze. The elevated plusmaze consisted of two open arms
and two closed arms with an elevation of 30 cm from the ground. Each
arm was 10 cm 
 40 cm. Mice were placed in the center of an elevated
plus maze facing an open arm and videotaped for 15 min. The total time
spent on the open arms versus the close arms were recorded and calcu-
lated. Two-way ANOVA was used to determine whether the differences
between genotype/treatment were statistically significant.
Marble-burying test. The marble-burying test was performed as de-
scribed previously (Deacon, 2006). Mice were placed and left for 30 min
in a cage with5 cm deep of bedding and 2 rows of marbles with regular
spacing in between. The marbles that were buried (to 2/3 of their depth)
or displaced from their original positions were counted. Two-way
ANOVA was used to determine whether the differences between geno-
type/treatment were statistically significant.
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Results
We first measured chemically induced mGluR-LTD at Schaffer
collateral–CA1 synapses using hippocampal slices fromP30–P35
mice as described previously (Huber et al., 2001). At this age,
Mecp2 KO mice in our colony exhibited no hindlimb clasping,
few tremor and mobility problems, and were considered to be
“early symptomatic.”mGluR-LTD can be induced by brief appli-
cation of the selectivemGluR1/5 agonist DHPGor by repetitively
stimulating Schaffer collateral axons using paired pulses (50 ms
interval) at 1 Hz (PP-LFS). A previous study using a loss-of-
function RTTmodel (Mecp2308/y mice) showed that DHPG-LTD
magnitude was not altered, whereas PP-LFS-LTD was impaired
(Moretti et al., 2006). The discrepancy is likely due to the fact
that the PP-LFS protocol is dependent on presynaptic glut-
amate release to induce LTD and both Mecp2308/y mice and
Mecp2 KO mice have presynaptic neurotransmission abnormal-
ities (Moretti et al., 2006, Calfa et al., 2011; J.T. and M.F.B., un-
published observations). Because our interest was in postsynaptic
regulation of protein synthesis, we reexamined the effects of
DHPG in the presence and absence of cycloheximide (CHX), an
mRNA translation inhibitor. We confirmed the finding that ap-
plication of DHPG induces a similar magnitude of LTD in both
WT and Mecp2 KO littermates (Fig. 1a). However, whereas
mGluR-LTD was diminished in WT mice by application of
CHX, in Mecp2 KO mice, mGluR-LTD was insensitive to CHX
treatment (Fig. 1b). This phenotype is reminiscent of mGluR-
LTD defects reported in mouse models of fragile X syndrome
(Fmr1 /y), 16p11.2 microdeletion (16p11.2 df/), and Syngap1
haploinsufficiency (Huber et al., 2002, Auerbach et al., 2011,
Barnes et al., 2015, Tian et al., 2015), which has been interpreted
as arising from increased basal synthesis of proteins that are nor-
mally rate limiting for LTD.
To examine global protein translation directly, we measured
bulk protein synthesis of hippocampal slices in the presence of
the transcription inhibitor actinomycin D (Osterweil et al.,
2010). Compared with yokedWT littermate controls,Mecp2 KO
WT (n = 10)
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Figure 1. Mecp2 KO mice exhibited dysregulated protein-synthesis-dependent mGluR-LTD in hippocampus. a, DHPG (50 M; 5 min) induced comparable magnitudes of mGluR-LTD in
hippocampal slices of P30P35 littermate WT (22.1 1.6%, n 10 mice) andMecp2 KO (22.7 1.4%, n 11). b, The protein synthesis inhibitor CHX significantly reduced mGluR-LTD in WT
(11.0 4%, n 10mice), but did not alter mGluR-LTD inMecp2 KO (20.9 1.6%, n 11). Statistics: 2-way ANOVA, interaction p 0.031, genotype p 0.021, treatment p 0.006. Tukey’s
multiple-comparisons test WT vs WTCHX **, KO vs KOCHX ns (in this and subsequent figures, *p 0.05; **p 0.01; ***p 0.001). c, Metabolic labeling of P30P35 hippocampal slices
revealed a significant increase in basal protein synthesis inMecp2 KO mice (KO: 113 10%, n 22 mice) compared with WT littermate (WT: 100 8.4%, n 22) (paired t test, p 0.03). d,
ERK1/2phosphorylationwere comparable betweenP30P35WTandMecp2KOhippocampal slices stimulatedwithDHPG (50M, 5min) (WT: 1004.6%,WTDHPG: 1223.9%,KO: 95.7
4.9%, KODHPG: 123.5 4.2%, n 17 animals for bothWT and KO) (2-way ANOVA, treatment p 0.0001, interaction and genotype n.s, Sidak’smultiple-comparisons testWT vsWTDHPG,
p 0.001, KO vs KO DHPG, p 0.0005). e, AKT phosphorylationwas comparable between P30P35WT andMecp2 KO hippocampal slices stimulatedwith insulin (1M, 10min) (WT: 100
9.6%,WT insulin: 200 21%, KO: 108 11.7%, KO insulin: 209 17.6%, n 4 animals for bothWT and KO) (2-way ANOVA, treatment p 0.0009, interaction and genotype n.s., Sidak’s
multiple-comparisons test WT versus WTDHPG, p 0.05, KO vs KODHPG, p 0.05). f, Normalized ratio of mGluR5 expression level to total protein amount between P30P35 WT and KO
littermates was not significantly altered (WT: 1 3.7%, n 9; KO: 95 4.0%, n 9, 2-tailed paired t test p 0.459). g, Normalized ratio of mGluR1 expression level to total protein amount
between P30P35WT and KO littermates was not significantly altered (WT: 100 9.8%, n 9; KO: 115.6 15.6%, n 9, 2-tailed paired t test p 0.328).
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mice showed a small but significant increase in 35S-methionine/
cysteine incorporation indicative of enhanced basal protein
translation (Fig. 1c). However, we observed no difference in basal
or evoked levels of p-ERK (stimulated by DHPG), and p-AKT
(stimulated by insulin) in the mutant slices compared with those
fromWT littermates (Fig. 1d,e) and no differences in mGluR5 or
mGluR1 in hippocampal tissue lysates (Fig. 1f,g). Collectively,
these results indicate that the mGluR-ERK and AKT signaling
pathways are unaffected in early symptomatic stage Mecp2 KO
hippocampal slices and may not contribute to the elevated basal
protein synthesis. However, we cannot exclude the possibility
that signaling pathways may be altered in a cell-type-specific
manner. Western blotting with hippocampal slices provides lim-
ited information toward that end.
Bulk protein synthesis measurements and candidate protein
expression analysis (e.g.,Western blotting of individual proteins)
fromwhole hippocampus slices lack cell-type specificity and can-
not determine the identities of dysregulated mRNAs without
prior knowledge. Because the pyramidal neurons in CA1 are
those displaying the mGluR-LTD phenotype, it is highly desir-
able to identify translational dysregulation specifically in these
neurons in an unbiased manner. To this end, we used translating
ribosome affinity purification followed by RNA-sequencing
(TRAP-seq) to investigate the translatome in hippocampal CA1
neurons. Compared with standard RNA-seq analysis of specific
cell populations isolated by fluorescence-activated cell sorting or
laser dissection, TRAP-seq provides the unique advantage of cell-
type specific profiling of mRNAs from intact undisturbed brain
tissues (Doyle et al., 2008, Heiman et al., 2008, Sanz et al., 2009)
and measures the levels of mRNAs that are associated with ribo-
somes. To analyze hippocampal CA1 neurons, we used a BAC
transgenic mouse line with EGFP-L10a expression driven by a
cholecystokinin (Cck) promoter. Cck is a neuropeptide that in
hippocampus is widely expressed by pyramidal neurons in
fields CA1–3 and by a specific class of inhibitory interneuron.
However, in the Cck-bacTRAP line, hippocampal expression
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Figure2. Characterization of Cck-bacTRAP line and immunoprecipitation of ribosomeassociatedmRNAs fromhippocampal CA1neurons.a, Coronal section of a Cck-bacTRAPmousebrain stained
for GFP and Nissl. Inset picture is an immunohistochemistry image of hippocampus with antibodies against GFP (cyan) and NeuN (magenta) showing colocalization in CA1. Scale bar, 100m.
b, Volcanoplot analysis revealed transcripts specifically enriched in Cck-bacTRAP IP samples versus input samples (whole hippocampus lysates). Reddots represent transcripts thatwere significantly
enriched in IP samples (e.g., Cck) and blue dots represent transcripts that were significantly enriched in input samples (e.g., Gfap, Gad2). c, Quantification of expression levels of Slc17a7 (Vglut1,
excitatory neuronmarker), Gad1 (inhibitory neuronmarker), and Aldh1l1 (glial marker) across different bacTRAP lines expressing in different cell types: Cck (hippocampal CA1, from current study),
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more connected with each other than to other groups of genes are defined as PPI communities and are enclosed by the ovals bounded by dashed lines. (Figure legend continues.)
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of L10a-EGFP is limited to pyramidal neurons in area CA1
Fig. 2a; Doyle et al., 2008, http://gensat.org/TRAPFounderView.
jsp?founder_id93415&gene_id356	. We dissected the hip-
pocampus from Cck-bacTRAP mice and affinity purified
EGFP-L10a tagged ribosome-associatedmRNAs by immunopre-
cipitation (IP). Compared with whole hippocampal lysate sam-
ples (input), IP samples showed a very distinctive enrichment of
a subset of genes (e.g.,Cck) and depletion of genes associatedwith
glia (e.g., Gfap) and GABAergic interneurons (e.g., Gad2) (Fig.
2b).We further compared our results with theCck-bacTRAP line
with published datasets from TRAP lines that specifically label
cerebellar granule neurons (Nd1), Bergmann glia (Sept4), and
Purkinje neuron (Pcp2) (Melle´n et al., 2012). Immunoprecipi-
tated mRNAs from the Cck line expressed high levels of Slc17a7
(vesicular glutamate transporter, expressed only in glutamatergic
neurons), but very low levels of Gad1 (glutamic acid decarboxyl-
ase, enriched in Purkinje cells) and Aldh1l1 (aldehyde dehydro-
genase, a glial marker) (Fig. 2c). The robust enrichment of
glutamatergic neuronal markers compared with non-neuronal
and inhibitory neuronal markers demonstrates that the Cck-
bacTRAP line is suitable to study translating mRNA dysregula-
tion in hippocampal CA1 excitatory neurons.
Next, we crossed the Mecp2/ line with the Cck-bacTRAP
line to obtain Mecp2/y;Cck (WT) and Mecp2 /y;Cck (KO) lit-
termates.Mecp2 /y;Cckmice exhibited the same behavioral phe-
notypes and premature death as Mecp2 /y mice. We profiled
ribosome-bound mRNAs from four pairs of littermates (from
P37–P60) and identified transcripts that showed consistent sig-
nificant differential expression betweenMecp2KOmice and their
littermate WT controls (Fig. 3a,b). Loss of MeCP2 caused dys-
regulation of a cohort of mRNAs (n 263, false discovery rate
0.1) across multiple biological replicates (Fig. 3b). The majority
of the dysregulated transcripts were increased in the Mecp2 KO
(197 genes, 74.9%); the remaining transcripts were downregu-
lated (66 genes, 25.1%). This result indicates that, in hippocam-
pal CA1 neurons, MeCP2 acts predominantly as a repressor of
gene expression and suggests that the previously observed in-
creased bulk protein synthesis might be explained by increased
levels of mRNAs associated with translating ribosomes. Interest-
ingly, aberrantly upregulated genes (n  197, p  4.6 
 1034,
KS test), but not downregulated genes (n 66, p 0.21, KS test),
were significantly longer comparedwith unaltered genes detected
in hippocampal CA1 neurons (Fig. 3c). Therefore, our hip-
pocampal CA1 specific profiling data support the recent obser-
vations that MeCP2 represses long genes preferentially in
neurons (Sugino et al., 2014, Gabel et al., 2015). GO analysis of
genes upregulated in the KO (n  197) indicates that they are
significantly enriched for GO terms related to cytoskeleton orga-
nization and cellular/neuronal projection morphogenesis (Fig.
3d), which is consistent with previous GO analysis with commonly
upregulated genes from multiple published microarray and RNA-
sequencing datasets from various brain regions (Gabel et al., 2015).
In contrast, GO analysis of genes downregulated in theKO (n 66)
did not reveal any significant biological processes or pathways. To
visualize the known interactions among proteins encoded by up-
regulated genes, the data were analyzed using the GeNets algorithm
(Fig. 3e). This analysis revealed clustering of affected genes into six
distinct PPI communities, suggesting that some aberrantly upregu-
lated genes in Mecp2 KO mice may participate in the assembly of
macromolecular complexes that contribute synergistically to RTT
pathology. Further comparison of the PPI network of MeCP2-
repressed genes with the SFARI human autism gene database indi-
cated that32of197genesupregulated in theKOhavebeen identified
as genes mutated in ASD patients (Fisher’s exact test, p  2.38 

109, see Fig. 3e). Therefore, manyMeCP2-repressed genes identi-
fied in area CA1 by TRAP-seq are independently implicated as risk
alleles in ASDs.
Recent studies suggest that theRNA-bindingproteinFMRPpref-
erentially stalls ribosomes on translating mRNAs of long length
(Darnell et al., 2011, Gabel et al., 2015). We compared the genes
upregulated in the Mecp2 KO (197 genes) with FMRP-bound
mRNA targets (735 expressed in hippocampal CA1 neurons of the
original 842 genes) and observed a significant overlap of 49 genes
(24.9% of MeCP2 repressed genes, p 1.1
 1022, Fisher’s exact
test; Fig. 4a; representative validations by qPCR in Fig. 4b). In con-
trast, only 7 genes downregulated in the KO are also FMRP targets
(10.6%, p 0.033; Fig. 4a). The significant overlap between genes
upregulated in the Mecp2 KO and FMRP direct targets raises the
possibility thatMeCP2 and FMRPmight regulate a common group
of mRNAs at the transcriptional and translational levels, respec-
tively.Among the 49 genes that are FMRPdirect targets andupregu-
lated inMecp2KO, 14 genes have been identified as ASD risk genes
in the SFARI human autism gene database (Fisher’s exact test,
p  3.14 
 109). Interestingly, whereas the FMRP-bound genes
reported byDarnell et al. (2011) were significantly longer than non-
FMRP target genes, the 49 MeCP2-repressed/FMRP-bound genes
were even longer still (Fig. 4c).
Studies of the Fmr1 /y mouse have shown that the increased
protein synthesis caused by loss of FMRP in the hippocampus is
downstream of a signaling pathway recruited by activation of
mGluR5 (Osterweil et al., 2010, Bhakar et al., 2012). Chronic inhi-
bition ofmGluR5with a negative allostericmodulator can correct a
wide array of disease phenotypes in Fmr1KOmice (Michalon et al.,
2012). Because a significant portion of genes upregulated inMecp2
KO are FMRP targets, we wondered whether they also might be
subjected to regulation by the mGluR5 signaling pathway. We
therefore treatedMecp2KOmicewith either vehicle or anmGluR5-
negativeallostericmodulator (NAM),2-chloro-4-((2,5-dimethyl-1-
(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine
(CTEP) from P30 to P60 and investigated the molecular changes in
Mecp2KO(n 3 animals for KO treatedwithCTEP, n 2 animals
for KO treated with vehicle) hippocampal CA1 neurons by TRAP-
seq.UsingGSEA (Mootha et al., 2003, Subramanian et al., 2005),we
ranked genes according to their differential expression between ve-
hicle- versus CTEP-treated conditions. Interestingly, both the 49
shared MeCP2-repressed/FMRP targets and the total set of 197
genesupregulated in theMecp2KOshowedasignificant shift toward
the left side (vehicle-treated) of the ranked gene list, indicating that
CTEP treatment tends to reduce their expression levels in Mecp2
KO. In contrast, the 66 genes downregulated inMecp2KO as a gene
set showed a random distribution (Fig. 4d). These analyses indicate
that MeCP2-repressed genes, particularly those genes regulated by
bothMeCP2 and FMRP, might be specifically subject to regulation
by CTEP treatment.
PPI analysis of the genes that responded most to CTEP treat-
ment (108 leading edge genes, which are those on the left side of
4
(Figure legend continued.) Genes without known PPI are arrayed to the right side. This anal-
ysis identified six distinct PPI communities within 197 MeCP2-repressed genes. Each commu-
nity gene list is submitted to DAVID functional annotation tool. Community 1 is enriched for
actin cytoskeleton and neuron projection. Community 5 is enriched for actin binding, cell junc-
tion, and synapse. In addition, genes that are identified as SFARI ASD genes https://gene.sfari.
org/autdb/HG_Home.do	 are highlighted as larger nodes, whereas those overlapping with
FMRP-bound targets are highlighted in red. Gene names are indicated for those that are iden-
tified as SFARI ASD genes and/ or FMRP targets.
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102), respectively. Gene names are indicated for those that are enriched in the two pathways.
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the peak of enrichment score, indicated by
red dashed vertical lines in Fig. 4d) iden-
tified five distinct PPI communities, of
which community 1 is enriched for actin
binding, calmodulin binding, and cyto-
skeleton binding genes and community 2
is enriched for actin cytoskeleton organi-
zation (DAVID GO analysis of biological
processes). Additional pathway enrich-
ment analysis (using the Reactome and
KEGG pathway database) indicated that
these genes were enriched in two path-
ways: calcium signaling and NCAM sig-
naling for neurite out growth (Fig. 4e).
For example, Ryr2 and Itpr2 are both
involved in internal calcium release regu-
lation upon mGluR activation. Down-
regulation of both with CTEP treatment
may therefore tune down aberrant cal-
cium signaling. Together, these results
suggest that CTEP may have potential to
ameliorate Mecp2 KO symptoms pheno-
typically by modulating the expression of
a subset of MeCP2-repressed genes.
We next investigated the effect of
chronic CTEP treatment on a battery of
RTT phenotypes. One of the neurostruc-
tural hallmarks of RTT mice highly rele-
vant to cellular health is reduced neuronal
soma size, which had been reproducibly
observed across multiple loss-of-function
Mecp2 mutant mouse lines and cellular
RTTmodels (Taneja et al., 2009, Goffin et
al., 2012, Yazdani et al., 2012, Li et al.,
2013, Wang et al., 2013). Consistent with
the observation that many cytoskeleton
genes were aberrantly upregulated in
Mecp2 KO and tuned down by CTEP
treatment, we found that chronic treat-
mentwithCTEP significantly ameliorated
the CA1 soma size deficit observed in
Mecp2 KO mice at P45–P60 (Fig. 5a,b).
This effect appears to constitute a “res-
cue” of the mutant phenotype because
treatment was without any significant ef-
fect in the WT.
Chronic treatment with low-dose
CTEP starting at P30 also prolonged the
lifespan of RTT mice significantly (Fig.
5c).Mecp2 KOmice have severe cardiore-
spiratory deficits, with irregular breath
patterns and breath holding, recapitulat-
ing human patients symptoms and likely
contributing to premature mortality
(Katz et al., 2009, Tarquinio et al., 2015).
Therefore, we evaluated the breathing
patterns of awake, freely moving mice
at a symptomatic age (P45-P60) with
whole-body plethysmography. Analysis
of the interbreath intervals revealed that
CTEP treatment partially reduced long
breath holdings in the Mecp2 KO (1 s)
compared with vehicle-treated KO mice
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Figure 5. Chronic CTEP treatments ofMecp2 KOmice ameliorates hippocampal reduced soma size, prolongs lifespan, partially
reduces long breath holdings, and ameliorates IA deficits. a, CTEP treatment ameliorates reduced neuronal soma size shown by
averaged soma size by animals (WT_vehicle 100.17 1.52 n 7,WT_CTEP 101.51 1.48 n 4, KO_vehicle 91.99 2.3 n
7, KO_CTEP 99.11 1.09 n 7, 2-way ANOVA, interaction p 0.123, drug treatment p 0.028, genotype p 0.008, Sidak’s
multiple-comparisons test WT_vehicle vs WT_CTEP n.s., KO_vehicle vs KO_CTEP *). b, CTEP treatment ameliorates reduced
neuronal soma size in hippocampal CA1 neurons shown in cumulative distribution by cell numbers [KS test: WT_CTEP (n 322
cells) vs WT_vehicle (n 500 cells) p 0.346, KO_vehicle vs WT_vehicle p 0, KO_vehicle (n 419 cells) vs KO_CTEP (n
483 cells) p 9.08
 1012, KO_CTEP vs WT_vehicle p 0.042]. c, Kaplan–Meier survival curve showed thatMecp2 KOmice
with treated CTEP survived longer than littermates treated with vehicle (KO_vehicle: n 11 median survival is 83 d, KO_CTEP:
n  11, median survival is 113 d. Log-rank test, p  0.038). d, Whole-body plethysmography analyses showed that CTEP
treatment may partially reduce long breath holdings (1 s) in Mecp2 KO mice (WT_vehicle 0.355 0.118, n 8; WT_CTEP
0.244 0.056, n 7; KO_vehicle 1.159 0.218, n 11; KO_CTEP 0.663 0.129, n 11; 2-way ANOVA, interaction p
0.251, treatmentp0.0748, genotypep0.0008, Tukey’smultiple-comparisons testWT_vehicle vsKO_vehicle **, KO_vehicle
vs WT_CTEP **, WT_CTEP vs KO_CTEP n.s., WT_vehicle vs KO_CTEP ns, WT_vehicle vs WT_CTEP n.s., KO_vehicle vs KO_CTEP
n.s.). e, CTEP treatment ameliorated IA deficits in Mecp2 KO mice. CTEP treatment did not alter acquisition of IA in WT mice
(WT_vehicle: 0 h 37.26 8.26 n 8, 24 h 217.36 36.32 n 8; 48 h 237.95 71.17; WT_CTEP: 0 h 46.45 7.92, 24 h
288.4847.71, 48h193.6146.36,n13, 2-wayRM-ANOVA, interactionp0.286, treatmentp0.794, timep0.0001;
Sidak’smultiple-comparisons test: 0 h vs 24 h **, 0 h vs 48 h **, 24 h vs 48 h ns,WT_vehicle n 8; 0 h vs 24 h ****, 0 h vs 48 h **,
24 h vs 48 h n.s., WT_CTEP n 13). CTEP treatment ameliorated acquisition deficits inMecp2 KOmice (KO_vehicle: 0 h 28.59
7.04, 24h86.620.62, 48h52.2120.00n8; KO_CTEP: 0h49.1610.73, 24h130.2216.80, 48h121.2928.81,n
11; 2-way RM-ANOVA, interaction p 0.383, treatment p 0.036, time p 0.001; Sidak’s multiple-comparisons test: KO_ve-
hicle n 8, 0 h vs 24 h n.s., 0 h vs 48 h n.s., 24 h vs 48 h n.s.; KO_CTEP n 11, 0 h vs 24 h **, 0 h vs 48 h **, 24 h vs 48 h n.s.;
KO_vehicle vs KO_CTEP 48 h *).
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Figure 6. CTEP treatment ofMecp2 KOmice does not improve bodyweight, tremor, hindlimb clasping, mobility, or anxiety deficits. a, b, CTEP treatment does not improve bodyweight, tremor,
hindlimb clasping, or mobility on an open bench (severity score: 0 equals WT, 1 is partially impaired, 2 is severely impaired). c, Open-field test showing thatMecp2 KO mice traveled less than WT
littermates in a 20minwindow regardless of vehicle or CTEP treatment (2-way ANOVA, genotype p 0.0025, treatment and interaction ns,WT_V n 7,WT_CTEP n 7, KO_V n 11, KO_CTEP
n10). The sameopen-field test also showed thatMecp2KOmice spent less time in the center versusmargin of the test arena comparedwithWT littermates regardless of vehicle or CTEP treatment
(2-way ANOVA, genotype p 0.0006, treatment and interaction not significant, WT_V n 5,WT_CTEP n 5, KO_V n 7, KO_CTEP n 8). d, Open-field test on the first day divided into bins
of 5 min showed that, whereasWT littermate ran themost distance during the first 5 min and then gradually reduced exploration,Mecp2 KOmice did not reach peak exploration until 10 min later
(2-wayRM-ANOVA,WT_VvsKO_V: interactionp0.0004, timep0.0001, genotypep0.103; KO_VvsKO_CTEP: interactionp0.0591, timep0.0093, treatmentp0.8284).Open-field
test on2 consecutivedays showed thatbothWTandKOmice regardless of drug treatmenthabituated to theenvironment (2-wayRM-ANOVA,WT_VvsKO_V: interactionp0.776, timep0.003,
genotypep0.22; KO_VvsKO_D: interactionp0.737, timep0.0003, treatmentp0.477).e, Regardless of CTEP treatment, comparedwithWT,Mecp2KOmice spentmore time in theopen
arm than in the closed arm in the elevated plus maze (WT_vehicle_open arm: 0.033  0.013 n  5; WT_CTEP_open arm: 0.121  0.027 n  7; (Figure legend continues.)
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(Fig. 5d), potentially contributing to the improvement in
lifespan.
Next, we tested themice in a hippocampus-dependent behav-
ioral assay, inhibitory avoidance (IA), which had been shown to
reveal cognitive deficits in mouse models of FX and 16p11.2 mi-
crodeletion (Do¨len et al., 2007, Tian et al., 2015) and requires
proper protein synthesis (Quevedo et al., 1999). The IA training
apparatus comprises a box with two chambers separated by a
door. One chamber is brightly lit and the other dark. Mice are
placed in the lit chamber before the door is opened to allow entry
into the dark side. Upon entry to the dark side, the animals re-
ceive a foot shock. They later demonstrate memory for this expe-
rience by avoiding the dark side when given the opportunity to
enter. Memory acquisition and strength are estimated by the la-
tency to enter the dark chamber at 24 and 48 h after training.
Mecp2KOmice andWT littermates show comparable sensitivity
to the foot shock as measured by the amount of wild running 2 s
after the shock. However, the mutants display a severe cognitive
deficit, with no significant increase in latency when tested 24 or
48 h later (Fig. 5e), even when tested at P30, before symptom
onset. CTEP treatment from P16–P30 may have modestly im-
proved cognitive performance because significant increases in
latency were observed at 24 and 48 h, although this improvement
fell far short of performance in WT mice (Fig. 5e).
Assays of several other RTT phenotypes failed to reveal an
effect of CTEP treatment.Weeklymanual scoring of bodyweight,
tremor, hindlimb clasping, and mobility on an open bench
showed no significant improvement (Fig. 6a,b). Open-field tests
showed that, regardless of drug treatment,Mecp2 KOmice trav-
eled less distance, particularly in the first 5 min of the test session
(Fig. 6c,d). They also spent less time in the center versus the
margin of the arena, indicating possible decreased locomotor
activity or increased anxiety. However,Mecp2 KOmice explored
less on the second day compared with the first day in the same
open arena, indicating normal habituation to the arena. We fur-
ther tested anxiety using the elevated plus maze. Interestingly,
Mecp2KOmice spentmore time on the open arm than the closed
arm regardless of drug treatment, which is usually interpreted as
a reduced level of anxiety (Fig. 6e). In the marble-burying assay,
CTEP treatment had a small and statistically nonsignificant ame-
lioration effect on the numbers of marbles that had been dis-
placed from their original positions, although the numbers of
marbles that were completely buried did not increase signifi-
cantly (Fig. 6f). Furthermore, CTEP treatment had little effect in
contextual fear conditioning tests in which Mecp2 KO mice also
had been shown to have severe deficits (Fig. 6g). Together, these
behavioral analyses indicate that the beneficial effects of CTEP
treatment were restricted to a narrow range of phenotypes, pos-
sibly reflecting regional variations in the brain pathophysiology
responsible for the diverse manifestations of the disease. Unlike
fragile X, excessive consequences of mGluR5 activation are not a
thread that connects a wide array of phenotypes in RTT.
Discussion
Dysregulated hippocampal mGluR-LTD and protein synthesis
have been demonstrated in several mouse lines carrying gene
mutations that cause human ASD and ID, including the models
for FXS, TSC, and 16p11.2 microdeletion (Huber et al., 2002,
Auerbach et al., 2011, Tian et al., 2015). In the current study, we
demonstrate that protein-synthesis-dependent mGluR-LTD is
also affected in a mouse model of RTT. Although hippocampal
mGluR-LTD per se may not be a core mechanism for the expres-
sion of ASD or ID, it has proven to be a very sensitive assay to
study postsynaptic protein translation regulation. Together,
these LTD studies support the hypothesis that altered translation
regulation may be a shared consequence of diverse gene muta-
tions that manifest in humans as ASD and intellectual disability.
Because the dependence of mGluR-LTD on protein synthesis
varies with age in mouse and rat, whether various mGluR-LTD
phenotypes in ASD mouse models reflect neuronal maturation
deficits needs further investigation.
In addition to bulk protein synthesis analyses, here we ana-
lyzed mRNAs associated with ribosomes specifically in hip-
pocampal CA1 neurons in an unbiased manner for the first time.
Compared with WT littermates, the majority of altered mRNAs
were upregulated inMecp2 KOmice, consistent with an increase
in active translation. It is likely that the increased bulk protein
synthesis is a downstream effect of loss of transcription repres-
sion in the absence of MeCP2, preferentially on long genes. It is
both interesting and reassuring to observe that our TRAP-seq
results from hippocampal CA1 neurons, revealing robust up-
regulation of long genes, are remarkably consistent with the find-
ings from multiple gene expression datasets using various crude
brain tissue lysates (Gabel et al., 2015). Our data support the
conclusion that the derepression of long genes occurs specifically
in excitatory hippocampal neurons in RTT mice. This under-
scores the power of studying cell-type-specific translating
mRNAs, which bypasses the difficulty of deducing neuronal spe-
cific signals from mixed cell populations from brain tissue.
The significant overlap between MeCP2-repressed genes and
FMRPdirect targets suggests thatMeCP2 andFMRPmight regulate
a common group ofmRNAs at the transcriptional and translational
levels, respectively. Functional annotations of MeCP2-repressed/
FMRP direct target genes revealed multiple genes involved in cyto-
skeletonorganization and cellmorphogenesis. For example,Myh10,
Myo5a,Myo18a, Dync1h1, Kif1a, Ank2, and Ank3 play key roles in
activities such as transport of synaptic vesicles, spine morphology,
and dynamics. Importantly, a significant part of MeCP2-repressed/
FMRP direct target genes belong to SFARI genes that have direct
implications inASDs (e.g.,Ank2,Ank3,Dscam,Dst,Herc2,Reln, and
Wdyf3, etc.). SignalingviamGluR5hasbeen implicated in thepatho-
physiology of fragile X and a number of disorders that manifest as
ASD (Wenger et al., 2016). We find that the majority of MeCP2-
repressed genes (both FMRP targets and non-FMRP targets) as a
gene set may be tuned down by chronic CTEP treatment, establish-
ing a potential mechanistic link between MeCP2-dependent tran-
scription repression and mGluR-dependent translation regulation.
4
(Figure legend continued.) KO_vehicle_open arm: 0.752 0.065 n 7; KO_CTEP_open
arm: 0.725 0.102 n 5;WT_vehicle_closed arm: 0.749 0.034 n 5;WT_CTEP_closed
arm: 0.675  0.067 n  7; KO_vehicle_closed arm: 0.177  0.056 n  7; KO_CTEP_
closed arm: 0.216 0.078 n 5, 2-way ANOVA, genotype p 0.0001). f, Mecp2 KO mice
were impaired in a marble-burying test and CTEP treatment did not significantly improve the
displacement of marbles (2-way ANOVA, only genotype is significant for both marbles that are
moved and marbles that are displaced, p 0.0001). g, WT mice regardless of CTEP treatment
showed robust freezing behavior in the same context but little freezing in a different context
(WT_vehicle_same context: 28.26 6.3% n 5; WT_CTEP_same conext: 38.26 3.64%
n 5; WT_vehicle_different context: 11.84 3.18% n 3; WT_CTEP_different context:
9.23 1.72% n 2). Mecp2 KO mice regardless of CTEP treatment showed little freezing
behavior in either the sameordifferent context (KO_vehicle_samecontext: 3.481.44%n
5; KO_CTEP_same context: 7.29  3.18% n  6; KO_vehicle_different context: 0.25 
0.15% n 2; KO_CTEP_different context: 7.34 4.12% n 3). Comparison ofWT and KO in
the same context condition: 2-way ANOVA, interaction p 0.45, treatment p 0.099, geno-
type p 0.0001.
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Further investigation is needed to address the biological functions of
those individual target genes.
Our TRAP-seq result provides a snapshot of mRNAs actively
engaged with ribosomes and presumably undergoing active
translation, likely reflecting the transcriptional level regulation by
MeCP2. The data support the conclusion that MeCP2 represses
transcription preferentially on a group of long genes in hip-
pocampal CA1 neurons and offers an explanation for the slight
increase in basal translation observed in hippocampal slices from
the KO. The TRAP-seq result by itself, however, cannot be taken
as indicative of translational efficiency because it does not pro-
vide quantitative ribosome occupancy information as ribosome
profiling does in cultured cells, which requires much larger input
materials (Li et al., 2014). Furthermore, protein synthesis regula-
tion is tightly regulated by neural activity (Ebert and Greenberg,
2013) and, in addition to the increased protein synthesis observed
here, the hippocampus from Mecp2 KO mice shows increased
network excitability (Calfa et al., 2011, McLeod et al., 2013). In
contrast, hESC-derived MeCP2 mutant neurons in culture show
a global downregulation of transcription and translation and hy-
poactivity (Li et al., 2013). Because Mecp2 KO mice display in-
creased or decreased activity level among different brain regions
asmeasured by the immediate early gene c-fos (Kron et al., 2012),
it is likely that protein synthesis level may also exhibit brain re-
gion variation.
Recent work reported that themTOR/AKT signaling pathway
was impaired in Mecp2 KO mice as well as in cultured human
embryonic stem cell-derived RTT neurons (Ricciardi et al., 2011,
Li et al., 2013). Insulin-like growth factor 1 (IGF-1) was reported
to alleviate a variety of symptoms inMecp2 KOmice by enhanc-
ing the mTOR/AKT pathway (Tropea et al., 2009, Castro et al.,
2014). Although we did not observe downregulation of the AKT
signaling pathway in ourMecp2mouse colony, it is interesting to
note that increasing mTOR signaling can ameliorate excessive
mGluR5-dependent protein synthesis in fragile X (Auerbach et
al., 2011, Bhakar et al., 2012) and could function similarly inRTT.
Excessive protein synthesis in fragile X is also corrected by
chronic inhibition of mGluR5 using CTEP (Michalon et al.,
2012). In the Mecp2 KO mice, we found that chronic low-dose
CTEP treatment prolongs lifespan,mildly ameliorates IA deficits,
and rescues the reduced soma size of hippocampal CA1 neurons.
Further work needs to address the possible effects of CTEP treat-
ment beyond the hippocampus; for example, the cardiorespira-
tory system, which has more direct relevance to general health.
However, the limited effect of CTEP treatment on most of the
other behavioral and cognitive aspects of the RTT mouse model
highlights the challenge of identification and correction of the
widespread core deficits of RTT.
References
Auerbach BD, Osterweil EK, BearMF (2011) Mutations causing syndromic
autism define an axis of synaptic pathophysiology. Nature 480:63–68.
CrossRef Medline
Barnes SA, Wijetunge LS, Jackson AD, Katsanevaki D, Osterweil EK,
Komiyama NH, Grant SG, Bear MF, Na¨gerl UV, Kind PC, Wyllie DJ
(2015) Convergence of hippocampal pathophysiology in Syngap/
and Fmr1-/y mice. J Neurosci 35:15073–15081. CrossRef Medline
Ben-Shachar S, Chahrour M, Thaller C, Shaw CA, Zoghbi HY (2009) Mouse
models ofMeCP2 disorders share gene expression changes in the cerebellum
and hypothalamus. HumMol Genet 18:2431–2442. CrossRefMedline
Bhakar AL, Do¨len G, BearMF (2012) The pathophysiology of fragile X (and
what it teaches us about synapses). Annu Rev Neurosci 35:417–443.
CrossRef Medline
Bozdagi O, Sakurai T, Dorr N, Pilorge M, Takahashi N, Buxbaum JD (2012)
Haploinsufficiency of Cyfip1 produces fragile X-like phenotypes in mice.
PLoS One 7:e42422. CrossRef Medline
Calfa G, Hablitz JJ, Pozzo-Miller L (2011) Network hyperexcitability in hip-
pocampal slices from Mecp2 mutant mice revealed by voltage-sensitive
dye imaging. J Neurophysiol 105:1768–1784. CrossRef Medline
Castro J, Garcia RI, Kwok S, Banerjee A, Petravicz J, Woodson J, Mellios N,
Tropea D, Sur M (2014) Functional recovery with recombinant human
IGF1 treatment in a mouse model of Rett syndrome. Proc Natl Acad Sci
U S A 111:9941–9946. CrossRef Medline
Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: from clinic to
neurobiology. Neuron 56:422–437. CrossRef Medline
Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008)
MeCP2, a key contributor to neurological disease, activates and represses
transcription. Science 320:1224–1229. CrossRef Medline
Chen L, Chen K, Lavery LA, Baker SA, Shaw CA, Li W, Zoghbi HY (2015)
MeCP2 binds to non-CG methylated DNA as neurons mature, influenc-
ing transcription and the timing of onset for Rett syndrome. Proc Natl
Acad Sci U S A 112:5509–5514. CrossRef Medline
Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-
CpGbinding protein-2 inCNSneurons results in aRett-like phenotype in
mice. Nat Genet 27:327–331. CrossRef Medline
Crittenden JR, Lacey CJ, Lee T, Bowden HA, Graybiel AM (2014) Severe
drug-induced repetitive behaviors and striatal overexpression of VAChT
in ChAT-ChR2-EYFP BAC transgenic mice. Front Neural Circuits 8:57.
CrossRef Medline
Darnell JC, VanDriesche SJ, ZhangC,HungKY,Mele A, Fraser CE, Stone EF,
Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB (2011)
FMRP stalls ribosomal translocation on mRNAs linked to synaptic func-
tion and autism. Cell 146:247–261. CrossRef Medline
Deacon RM (2006) Digging and marble burying in mice: simple methods
for in vivo identification of biological impacts. Nat Protoc 1:122–124.
CrossRef Medline
Do¨len G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF
(2007) Correction of fragile X syndrome in mice. Neuron 56:955–962.
CrossRef Medline
Doyle JP, Dougherty JD, HeimanM, Schmidt EF, Stevens TR, Ma G, Bupp S,
Shrestha P, Shah RD, Doughty ML, Gong S, Greengard P, Heintz N
(2008) Application of a translational profiling approach for the compar-
ative analysis of CNS cell types. Cell 135:749–762. CrossRef Medline
Ebert DH, Greenberg ME (2013) Activity-dependent neuronal signalling
and autism spectrum disorder. Nature 493:327–337. CrossRef Medline
GabelHW,Kinde B, StroudH,Gilbert CS,HarminDA, KastanNR,Hemberg
M, Ebert DH, Greenberg ME (2015) Disruption of DNA-methylation-
dependent long gene repression in Rett syndrome. Nature 522:89–93.
CrossRef Medline
Goffin D, Allen M, Zhang L, Amorim M, Wang IT, Reyes AR, Mercado-
Berton A, Ong C, Cohen S, Hu L, Blendy JA, Carlson GC, Siegel SJ,
Greenberg ME, Zhou Z (2012) Rett syndromemutationMeCP2 T158A
disrupts DNA binding, protein stability and ERP responses. Nat Neurosci
15:274–283. CrossRef Medline
Guo JU, Su Y, Shin JH, Shin J, Li H, Xie B, Zhong C, Hu S, Le T, Fan G, Zhu
H, Chang Q, Gao Y, Ming GL, Song H (2014) Distribution, recognition
and regulation of non-CpG methylation in the adult mammalian brain.
Nat Neurosci 17:215–222. CrossRef Medline
Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-
null mutation causes neurological symptoms that mimic Rett syndrome.
Nat Genet 27:322–326. CrossRef Medline
Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, Sua´rez-
Farin˜as M, Schwarz C, Stephan DA, Surmeier DJ, Greengard P, Heintz N
(2008) A translational profiling approach for themolecular characteriza-
tion of CNS cell types. Cell 135:738–748. CrossRef Medline
Heiman M, Kulicke R, Fenster RJ, Greengard P, Heintz N (2014) Cell type-
specific mRNA purification by translating ribosome affinity purification
(TRAP). Nat Protoc 9:1282–1291. CrossRef Medline
Huber KM, Kayser MS, Bear MF (2000) Role for rapid dendritic protein
synthesis in hippocampal mGluR-dependent long-term depression. Sci-
ence 288:1254–1257. CrossRef Medline
Huber KM, Roder JC, BearMF (2001) Chemical induction ofmGluR5- and
protein synthesis-dependent long-term depression in hippocampal area
CA1. J Neurophysiol 86:321–325. Medline
Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic
Tao et al. • Role for mGluR5 in Rett Syndrome Pathophysiology J. Neurosci., November 23, 2016 • 36(47):11946–11958 • 11957
plasticity in a mouse model of fragile X mental retardation. Proc Natl
Acad Sci U S A 99:7746–7750. CrossRef Medline
Jordan C, Li HH, Kwan HC, Francke U (2007) Cerebellar gene expression
profiles of mouse models for Rett syndrome reveal novel MeCP2 targets.
BMCMed Genet 8:36. Medline
Katz DM, Dutschmann M, Ramirez JM, Hilaire G (2009) Breathing disor-
ders in Rett syndrome: progressive neurochemical dysfunction in the
respiratory network after birth. Respir Physiol Neurobiol 168:101–108.
CrossRef Medline
Kelleher RJ 3rd, Bear MF (2008) The autistic neuron: troubled translation?
Cell 135:401–406. CrossRef Medline
Kron M, Howell CJ, Adams IT, Ransbottom M, Christian D, Ogier M, Katz
DM (2012) Brain activity mapping inMecp2 mutant mice reveals func-
tional deficits in forebrain circuits, including key nodes in the default
mode network, that are reversed with ketamine treatment. J Neurosci
32:13860–13872. CrossRef Medline
Lewis JD,Meehan RR,HenzelWJ,Maurer-Fogy I, Jeppesen P, Klein F, Bird A
(1992) Purification, sequence, and cellular localization of a novel chro-
mosomal protein that binds to methylated DNA. Cell 69:905–914.
CrossRef Medline
Li GW, Burkhardt D, Gross C, Weissman JS (2014) Quantifying absolute
protein synthesis rates reveals principles underlying allocation of cellular
resources. Cell 157:624–635. CrossRef Medline
Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Love´n J, Kwok SM, Feld-
man DA, Bateup HS, Gao Q, Hockemeyer D, Mitalipova M, Lewis CA,
Vander Heiden MG, Sur M, Young RA, Jaenisch R (2013) Global tran-
scriptional and translational repression in human-embryonic-stem-cell-
derived Rett syndrome neurons. Cell Stem Cell 13:446–458. CrossRef
Medline
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change
and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550.
CrossRef Medline
McLeod F, Ganley R, Williams L, Selfridge J, Bird A, Cobb SR (2013) Re-
duced seizure threshold and altered network oscillatory properties in a
mouse model of Rett syndrome. Neuroscience 231:195–205. CrossRef
Medline
Melle´n M, Ayata P, Dewell S, Kriaucionis S, Heintz N (2012) MeCP2 binds
to 5hmC enriched within active genes and accessible chromatin in the
nervous system. Cell 151:1417–1430. CrossRef Medline
Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG,
Jaeschke G, Bear MF, Lindemann L (2012) Chronic pharmacological
mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49–56.
CrossRef Medline
Mootha VK et al. (2003) PGC-1alpha-responsive genes involved in oxida-
tive phosphorylation are coordinately downregulated in human diabetes.
Nat Genet 34:267–273. CrossRef Medline
Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, Antalffy B, Arm-
strong D, Arancio O, Sweatt JD, Zoghbi HY (2006) Learning and mem-
ory and synaptic plasticity are impaired in a mouse model of Rett
syndrome. J Neurosci 26:319–327. CrossRef Medline
Osterweil EK, Krueger DD, Reinhold K, BearMF (2010) Hypersensitivity to
mGluR5 and ERK1/2 leads to excessive protein synthesis in the hip-
pocampus of amousemodel of fragile X syndrome. J Neurosci 30:15616–
15627. CrossRef Medline
Quevedo J, ViannaMR, Roesler R, de-Paris F, Izquierdo I, Rose SP (1999) Two
time windows of anisomycin-induced amnesia for inhibitory avoidance
training in rats: protection fromamnesiabypretrainingbutnotpre-exposure
to the task apparatus. LearnMem 6:600–607. CrossRefMedline
Ricciardi S, Boggio EM,Grosso S, Lonetti G, Forlani G, Stefanelli G, Calcagno
E,Morello N, Landsberger N, Biffo S, Pizzorusso T, GiustettoM, Broccoli
V (2011) ReducedAKT/mTOR signaling and protein synthesis dysregu-
lation in a Rett syndrome animal model. HumMol Genet 20:1182–1196.
CrossRef Medline
Samaco RC, McGraw CM, Ward CS, Sun Y, Neul JL, Zoghbi HY (2013)
Female Mecp2(/-) mice display robust behavioral deficits on two dif-
ferent genetic backgrounds providing a framework for pre-clinical stud-
ies. HumMol Genet 22:96–109. CrossRef Medline
Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS (2009) Cell-
type-specific isolation of ribosome-associated mRNA from complex tis-
sues. Proc Natl Acad Sci U S A 106:13939–13944. CrossRef Medline
Skene PJ, IllingworthRS,Webb S, Kerr AR, JamesKD, TurnerDJ, AndrewsR,
Bird AP (2010) Neuronal MeCP2 is expressed at near histone-octamer
levels and globally alters the chromatin state. Mol Cell 37:457–468.
CrossRef Medline
Subramanian A, Tamayo P,Mootha VK,Mukherjee S, Ebert BL, GilletteMA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005)
Gene set enrichment analysis: a knowledge-based approach for interpret-
ing genome-wide expression profiles. Proc Natl Acad Sci U S A 102:
15545–15550. CrossRef Medline
Sugino K, Hempel CM, Okaty BW, Arnson HA, Kato S, Dani VS, Nelson SB
(2014) Cell-type-specific repression bymethyl-CpG-binding protein 2 is
biased toward long genes. J Neurosci 34:12877–12883. CrossRef Medline
Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L, SantistevanNJ, LiW, Zhao X,
Jin P (2010) Cross talk between microRNA and epigenetic regulation in
adult neurogenesis. J Cell Biol 189:127–141. CrossRef Medline
Taneja P, Ogier M, Brooks-Harris G, Schmid DA, Katz DM, Nelson SB
(2009) Pathophysiology of locus ceruleus neurons in a mouse model of
Rett syndrome. J Neurosci 29:12187–12195. CrossRef Medline
Tarquinio DC,HouW,Neul JL, KaufmannWE, Glaze DG,Motil KJ, Skinner
SA, Lee HS, Percy AK (2015) The Changing Face of Survival in Rett
Syndrome and MECP2-Related Disorders. Pediatr Neurol 53:402–411.
CrossRef Medline
Tian D, Stoppel LJ, Heynen AJ, Lindemann L, Jaeschke G, Mills AA, Bear MF
(2015) Contribution ofmGluR5 to pathophysiology in amousemodel of
human chromosome 16p11.2 microdeletion. Nat Neurosci 18:182–184.
CrossRef Medline
Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery
R, JaenischR, SurM (2009) Partial reversal of Rett syndrome-like symp-
toms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 106:2029–2034.
CrossRef Medline
TudorM, Akbarian S, Chen RZ, Jaenisch R (2002) Transcriptional profiling of
a mouse model for Rett syndrome reveals subtle transcriptional changes in
the brain. Proc Natl Acad Sci U S A 99:15536–15541. CrossRefMedline
Wang IT, Reyes AR, Zhou Z (2013) Neuronal morphology in MeCP2
mouse models is intrinsically variable and depends on age, cell type, and
Mecp2 mutation. Neurobiol Dis 58:3–12. CrossRef Medline
Wenger TL, Kao C, McDonald-McGinn DM, Zackai EH, Bailey A, Schultz
RT, Morrow BE, Emanuel BS, Hakonarson H (2016) The role of
mGluR copy number variation in genetic and environmental forms of
syndromic autism spectrum disorder. Sci Rep 6:19372. CrossRef
Medline
Wu H, Tao J, Chen PJ, Shahab A, Ge W, Hart RP, Ruan X, Ruan Y, Sun YE
(2010) Genome-wide analysis reveals methyl-CpG-binding protein
2-dependent regulation of microRNAs in a mouse model of Rett syn-
drome. Proc Natl Acad Sci U S A 107:18161–18166. CrossRef Medline
Yazdani M, Deogracias R, Guy J, Poot RA, Bird A, Barde YA (2012)
Disease modeling using embryonic stem cells: MeCP2 regulates nu-
clear size and RNA synthesis in neurons. Stem Cells 30:2128–2139.
CrossRef Medline
11958 • J. Neurosci., November 23, 2016 • 36(47):11946–11958 Tao et al. • Role for mGluR5 in Rett Syndrome Pathophysiology
